Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications

Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart failure (HF) pathology, contributing to disease development, progression, and outcomes. The pathophysiological mechanisms linking CMD to HF are complex and still not completely understood and include chronic i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2024-07, Vol.25 (14), p.7628
Hauptverfasser: La Vecchia, Giulia, Fumarulo, Isabella, Caffè, Andrea, Chiatto, Mario, Montone, Rocco A, Aspromonte, Nadia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 14
container_start_page 7628
container_title International journal of molecular sciences
container_volume 25
creator La Vecchia, Giulia
Fumarulo, Isabella
Caffè, Andrea
Chiatto, Mario
Montone, Rocco A
Aspromonte, Nadia
description Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart failure (HF) pathology, contributing to disease development, progression, and outcomes. The pathophysiological mechanisms linking CMD to HF are complex and still not completely understood and include chronic inflammation, oxidative stress, and neurohormonal activation. Despite the diagnostic and prognostic relevance in patients with HF, there is no specific therapeutic strategy targeting CMD to date. Moreover, the diagnosis of this clinical condition is challenging. In this review article, we aim to discuss the different clinical pathogenetic mechanisms linking CMD to HF across the different spectra of these diseases, their prognostic relevance, and the possible therapeutic targets along with the remaining knowledge gaps in the field.
doi_str_mv 10.3390/ijms25147628
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3085115858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A803774029</galeid><sourcerecordid>A803774029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-d4cc79985a6a73e4eb76b8850207036792110547176d290adeea3503f6fbdc683</originalsourceid><addsrcrecordid>eNptkU1v1DAQhi1ERUvhxhlZ4tJDt_VHEjvcqoWllVqBRDlHs86k65UTB9tB2p_Av8bpFmgRmsOMZp53ZqSXkDecnUlZs3O77aMoeaEqoZ-RI14IsWCsUs8f1YfkZYxbxoQUZf2CHGZdphU_Ij9vrAn-B0QzOQj0wy5202CS9QOFPIiRpg3SryOaFKae-o5eIoREV2DdFJB-gbTxzt_t3u_LcbOL9r5xSpfODtaAoyuElOFIYWjp7QYDjDgla-hVP7pMzOfiK3LQgYv4-iEfk2-rj7fLy8X1509Xy4vrhZGcp0VbGKPqWpdQgZJY4FpVa61LJphislK14JyVheKqakXNoEUEWTLZVd26NZWWx-Rkv3cM_vuEMTW9jQadgwH9FBvJdMl5qcsZffcPuvVTGPJ3M1XUkjOt_lJ34LCxQ-dTADMvbS40k0oVTNSZOvsPlaPF3ho_YGdz_4ngdC-4tyFg14zB9hB2DWfN7Hzz2PmMv334dVr32P6Bf1stfwGU8qlT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084931087</pqid></control><display><type>article</type><title>Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications</title><source>MEDLINE</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>La Vecchia, Giulia ; Fumarulo, Isabella ; Caffè, Andrea ; Chiatto, Mario ; Montone, Rocco A ; Aspromonte, Nadia</creator><creatorcontrib>La Vecchia, Giulia ; Fumarulo, Isabella ; Caffè, Andrea ; Chiatto, Mario ; Montone, Rocco A ; Aspromonte, Nadia</creatorcontrib><description>Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart failure (HF) pathology, contributing to disease development, progression, and outcomes. The pathophysiological mechanisms linking CMD to HF are complex and still not completely understood and include chronic inflammation, oxidative stress, and neurohormonal activation. Despite the diagnostic and prognostic relevance in patients with HF, there is no specific therapeutic strategy targeting CMD to date. Moreover, the diagnosis of this clinical condition is challenging. In this review article, we aim to discuss the different clinical pathogenetic mechanisms linking CMD to HF across the different spectra of these diseases, their prognostic relevance, and the possible therapeutic targets along with the remaining knowledge gaps in the field.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms25147628</identifier><identifier>PMID: 39062871</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; Blood vessels ; Cardiovascular disease ; Dapagliflozin ; Development and progression ; Diabetes ; Diagnosis ; Ejection fraction ; Endothelium ; Health aspects ; Heart failure ; Heart Failure - etiology ; Heart Failure - pathology ; Heart Failure - physiopathology ; Heart Failure - therapy ; Humans ; Hypertension ; Inflammation ; Ischemia ; Ivabradine ; Kidney diseases ; Kinases ; Liraglutide ; Microcirculation ; Microvessels - pathology ; Microvessels - physiopathology ; Nitric oxide ; Oxidative Stress ; Pathology ; Pathophysiology ; Prognosis ; Smooth muscle ; Systemic diseases ; Trimetazidine ; Valsartan</subject><ispartof>International journal of molecular sciences, 2024-07, Vol.25 (14), p.7628</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c311t-d4cc79985a6a73e4eb76b8850207036792110547176d290adeea3503f6fbdc683</cites><orcidid>0009-0006-9800-0480 ; 0000-0001-5264-1043 ; 0000-0002-6439-1018</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39062871$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>La Vecchia, Giulia</creatorcontrib><creatorcontrib>Fumarulo, Isabella</creatorcontrib><creatorcontrib>Caffè, Andrea</creatorcontrib><creatorcontrib>Chiatto, Mario</creatorcontrib><creatorcontrib>Montone, Rocco A</creatorcontrib><creatorcontrib>Aspromonte, Nadia</creatorcontrib><title>Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart failure (HF) pathology, contributing to disease development, progression, and outcomes. The pathophysiological mechanisms linking CMD to HF are complex and still not completely understood and include chronic inflammation, oxidative stress, and neurohormonal activation. Despite the diagnostic and prognostic relevance in patients with HF, there is no specific therapeutic strategy targeting CMD to date. Moreover, the diagnosis of this clinical condition is challenging. In this review article, we aim to discuss the different clinical pathogenetic mechanisms linking CMD to HF across the different spectra of these diseases, their prognostic relevance, and the possible therapeutic targets along with the remaining knowledge gaps in the field.</description><subject>Animals</subject><subject>Blood vessels</subject><subject>Cardiovascular disease</subject><subject>Dapagliflozin</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Diagnosis</subject><subject>Ejection fraction</subject><subject>Endothelium</subject><subject>Health aspects</subject><subject>Heart failure</subject><subject>Heart Failure - etiology</subject><subject>Heart Failure - pathology</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Inflammation</subject><subject>Ischemia</subject><subject>Ivabradine</subject><subject>Kidney diseases</subject><subject>Kinases</subject><subject>Liraglutide</subject><subject>Microcirculation</subject><subject>Microvessels - pathology</subject><subject>Microvessels - physiopathology</subject><subject>Nitric oxide</subject><subject>Oxidative Stress</subject><subject>Pathology</subject><subject>Pathophysiology</subject><subject>Prognosis</subject><subject>Smooth muscle</subject><subject>Systemic diseases</subject><subject>Trimetazidine</subject><subject>Valsartan</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkU1v1DAQhi1ERUvhxhlZ4tJDt_VHEjvcqoWllVqBRDlHs86k65UTB9tB2p_Av8bpFmgRmsOMZp53ZqSXkDecnUlZs3O77aMoeaEqoZ-RI14IsWCsUs8f1YfkZYxbxoQUZf2CHGZdphU_Ij9vrAn-B0QzOQj0wy5202CS9QOFPIiRpg3SryOaFKae-o5eIoREV2DdFJB-gbTxzt_t3u_LcbOL9r5xSpfODtaAoyuElOFIYWjp7QYDjDgla-hVP7pMzOfiK3LQgYv4-iEfk2-rj7fLy8X1509Xy4vrhZGcp0VbGKPqWpdQgZJY4FpVa61LJphislK14JyVheKqakXNoEUEWTLZVd26NZWWx-Rkv3cM_vuEMTW9jQadgwH9FBvJdMl5qcsZffcPuvVTGPJ3M1XUkjOt_lJ34LCxQ-dTADMvbS40k0oVTNSZOvsPlaPF3ho_YGdz_4ngdC-4tyFg14zB9hB2DWfN7Hzz2PmMv334dVr32P6Bf1stfwGU8qlT</recordid><startdate>20240711</startdate><enddate>20240711</enddate><creator>La Vecchia, Giulia</creator><creator>Fumarulo, Isabella</creator><creator>Caffè, Andrea</creator><creator>Chiatto, Mario</creator><creator>Montone, Rocco A</creator><creator>Aspromonte, Nadia</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0006-9800-0480</orcidid><orcidid>https://orcid.org/0000-0001-5264-1043</orcidid><orcidid>https://orcid.org/0000-0002-6439-1018</orcidid></search><sort><creationdate>20240711</creationdate><title>Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications</title><author>La Vecchia, Giulia ; Fumarulo, Isabella ; Caffè, Andrea ; Chiatto, Mario ; Montone, Rocco A ; Aspromonte, Nadia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-d4cc79985a6a73e4eb76b8850207036792110547176d290adeea3503f6fbdc683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Blood vessels</topic><topic>Cardiovascular disease</topic><topic>Dapagliflozin</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Diagnosis</topic><topic>Ejection fraction</topic><topic>Endothelium</topic><topic>Health aspects</topic><topic>Heart failure</topic><topic>Heart Failure - etiology</topic><topic>Heart Failure - pathology</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Inflammation</topic><topic>Ischemia</topic><topic>Ivabradine</topic><topic>Kidney diseases</topic><topic>Kinases</topic><topic>Liraglutide</topic><topic>Microcirculation</topic><topic>Microvessels - pathology</topic><topic>Microvessels - physiopathology</topic><topic>Nitric oxide</topic><topic>Oxidative Stress</topic><topic>Pathology</topic><topic>Pathophysiology</topic><topic>Prognosis</topic><topic>Smooth muscle</topic><topic>Systemic diseases</topic><topic>Trimetazidine</topic><topic>Valsartan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>La Vecchia, Giulia</creatorcontrib><creatorcontrib>Fumarulo, Isabella</creatorcontrib><creatorcontrib>Caffè, Andrea</creatorcontrib><creatorcontrib>Chiatto, Mario</creatorcontrib><creatorcontrib>Montone, Rocco A</creatorcontrib><creatorcontrib>Aspromonte, Nadia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>La Vecchia, Giulia</au><au>Fumarulo, Isabella</au><au>Caffè, Andrea</au><au>Chiatto, Mario</au><au>Montone, Rocco A</au><au>Aspromonte, Nadia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-07-11</date><risdate>2024</risdate><volume>25</volume><issue>14</issue><spage>7628</spage><pages>7628-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart failure (HF) pathology, contributing to disease development, progression, and outcomes. The pathophysiological mechanisms linking CMD to HF are complex and still not completely understood and include chronic inflammation, oxidative stress, and neurohormonal activation. Despite the diagnostic and prognostic relevance in patients with HF, there is no specific therapeutic strategy targeting CMD to date. Moreover, the diagnosis of this clinical condition is challenging. In this review article, we aim to discuss the different clinical pathogenetic mechanisms linking CMD to HF across the different spectra of these diseases, their prognostic relevance, and the possible therapeutic targets along with the remaining knowledge gaps in the field.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39062871</pmid><doi>10.3390/ijms25147628</doi><orcidid>https://orcid.org/0009-0006-9800-0480</orcidid><orcidid>https://orcid.org/0000-0001-5264-1043</orcidid><orcidid>https://orcid.org/0000-0002-6439-1018</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2024-07, Vol.25 (14), p.7628
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_proquest_miscellaneous_3085115858
source MEDLINE; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animals
Blood vessels
Cardiovascular disease
Dapagliflozin
Development and progression
Diabetes
Diagnosis
Ejection fraction
Endothelium
Health aspects
Heart failure
Heart Failure - etiology
Heart Failure - pathology
Heart Failure - physiopathology
Heart Failure - therapy
Humans
Hypertension
Inflammation
Ischemia
Ivabradine
Kidney diseases
Kinases
Liraglutide
Microcirculation
Microvessels - pathology
Microvessels - physiopathology
Nitric oxide
Oxidative Stress
Pathology
Pathophysiology
Prognosis
Smooth muscle
Systemic diseases
Trimetazidine
Valsartan
title Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T10%3A32%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Microvascular%20Dysfunction%20across%20the%20Spectrum%20of%20Heart%20Failure%20Pathology:%20Pathophysiology,%20Clinical%20Features%20and%20Therapeutic%20Implications&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=La%20Vecchia,%20Giulia&rft.date=2024-07-11&rft.volume=25&rft.issue=14&rft.spage=7628&rft.pages=7628-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms25147628&rft_dat=%3Cgale_proqu%3EA803774029%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3084931087&rft_id=info:pmid/39062871&rft_galeid=A803774029&rfr_iscdi=true